Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin versus placebo in adults with type 2 diabetes mellitus and renal impairment
2007-004951-12Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Saxagliptin with Placebo (2 arms). Primary endpoints: Short-term treatment effect and tolerability and Long-term efficacy, safety, and tolerability. Started Nov 2007; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2007-004951-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004951-12.